Interpace Diagnostics Announces Closing of $7.0 Million Public Offering of Common Stock
January 29, 2019 16:20 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, N.J., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (Nasdaq: IDXG) (“Interpace” or the “Company”) today announced the closing of its previously announced...
Interpace Diagnostics Announces Pricing of $7.0 Million Public Offering of Common Stock
January 25, 2019 06:00 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, N.J., Jan. 25, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (Nasdaq: IDXG) (“Interpace” or the “Company”) today announced the pricing of an underwritten public offering of...
Interpace Diagnostics Announces Proposed Public Offering of Common Stock
January 24, 2019 16:35 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, N.J., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (Nasdaq: IDXG) (“Interpace” or the “Company”) announced today that it intends to offer and sell shares of its...
Interpace Diagnostics to Present at the Fifteenth Annual NobleCon
January 24, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG) today announced that Jack Stover, Chief Executive Officer, will present at NobleConXV - Noble Capital...
Interpace Diagnostics Announces Further Expansion of Thyroid Business
January 22, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Interpace Only Provider Validated to Offer MDx Tests on Three Distinct Platforms PARSIPPANY, NJ, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG) announced today that it...
Interpace Diagnostics Enters into Agreement with University of Maryland Medical System
January 14, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Agreement Provides Access to Company’s Available Molecular Diagnostic Tests PARSIPPANY, NJ, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG) has entered in to an...
Interpace Diagnostics Ranked as Top 10 Bioinformatics Solutions Provider
December 27, 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that CIO Applications, a publication focused on providing professionals with...
Interpace Announces Notice of Allowance from U.S. Patent and Trademark Office Covering BarreGEN®
December 17, 2018 06:50 ET
|
Interpace Diagnostics Group, Inc.
BarreGEN® is Interpace’s Lead Molecular Diagnostic Pipeline Product for Barrett’s Esophagus Parsippany, NJ, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace”)...
Interpace Diagnostics Launches New Websites
November 28, 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
New Design to Enhance Branding and Expand Social Media Outreach PARSIPPANY, NJ, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG) is pleased to announce the launch of...
Newly Published Data from National Study Supports Interpace Diagnostics’ PancraGEN®
November 26, 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
New Article in Peer-Reviewed Journal Highlights Important Role of PancraGEN® Testing PARSIPPANY, NJ, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)...